Biofrontera Stock Market Value
| BFRI Stock | USD 0.94 0.06 6.00% |
| Symbol | Biofrontera |
Biofrontera Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.16 | Revenue Per Share 11.573 | Quarterly Revenue Growth 0.34 | Return On Assets (0.40) | Return On Equity (1.49) |
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Biofrontera 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Biofrontera's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Biofrontera.
| 11/04/2024 |
| 12/04/2024 |
If you would invest 0.00 in Biofrontera on November 4, 2024 and sell it all today you would earn a total of 0.00 from holding Biofrontera or generate 0.0% return on investment in Biofrontera over 30 days. Biofrontera is related to or competes with Shuttle Pharmaceuticals, Akanda Corp, China Pharma, Sunshine Biopharma, Petros Pharmaceuticals, Evoke Pharma, and Cumberland Pharmaceuticals. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treat... More
Biofrontera Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Biofrontera's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Biofrontera upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.77 | |||
| Information Ratio | 0.0021 | |||
| Maximum Drawdown | 46.72 | |||
| Value At Risk | (11.70) | |||
| Potential Upside | 14.63 |
Biofrontera Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biofrontera's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Biofrontera's standard deviation. In reality, there are many statistical measures that can use Biofrontera historical prices to predict the future Biofrontera's volatility.| Risk Adjusted Performance | 0.0207 | |||
| Jensen Alpha | 0.3467 | |||
| Total Risk Alpha | (1.05) | |||
| Sortino Ratio | 0.0023 | |||
| Treynor Ratio | (0.06) |
Biofrontera Backtested Returns
Biofrontera is risky at the moment. Biofrontera secures Sharpe Ratio (or Efficiency) of 0.01, which signifies that the company had a 0.01% return per unit of risk over the last 3 months. We have found thirty technical indicators for Biofrontera, which you can use to evaluate the volatility of the firm. Please confirm Biofrontera's Risk Adjusted Performance of 0.0207, mean deviation of 6.3, and Downside Deviation of 7.77 to double-check if the risk estimate we provide is consistent with the expected return of 0.0871%. The firm shows a Beta (market volatility) of -2.18, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Biofrontera are expected to decrease by larger amounts. On the other hand, during market turmoil, Biofrontera is expected to outperform it. Biofrontera right now shows a risk of 8.7%. Please confirm Biofrontera sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Biofrontera will be following its price patterns.
Auto-correlation | -0.61 |
Very good reverse predictability
Biofrontera has very good reverse predictability. Overlapping area represents the amount of predictability between Biofrontera time series from 4th of November 2024 to 19th of November 2024 and 19th of November 2024 to 4th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Biofrontera price movement. The serial correlation of -0.61 indicates that roughly 61.0% of current Biofrontera price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.61 | |
| Spearman Rank Test | -0.67 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Biofrontera lagged returns against current returns
Autocorrelation, which is Biofrontera stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Biofrontera's stock expected returns. We can calculate the autocorrelation of Biofrontera returns to help us make a trade decision. For example, suppose you find that Biofrontera has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Biofrontera regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Biofrontera stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Biofrontera stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Biofrontera stock over time.
Current vs Lagged Prices |
| Timeline |
Biofrontera Lagged Returns
When evaluating Biofrontera's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Biofrontera stock have on its future price. Biofrontera autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Biofrontera autocorrelation shows the relationship between Biofrontera stock current value and its past values and can show if there is a momentum factor associated with investing in Biofrontera.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:Check out Biofrontera Correlation, Biofrontera Volatility and Biofrontera Alpha and Beta module to complement your research on Biofrontera. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Biofrontera technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.